Best Agrolife Ltd — Q1 FY27 earnings call
Summary generated by AI from the official transcript Best Agrolife Ltd filed with BSE on 04 Aug 2026. Every statement cites a verbatim quote from that document — open any citation to read it. This is a record of what management said, not a recommendation. How we check these summaries
The short read
Best Agrolife reported Q1 FY27 revenue from operations of Rs 396 crores, up 4% year-on-year, while EBITDA grew 70% to Rs 78 crores and profit after tax more than doubled to Rs 41 crores. Management attributed the margin improvement to a shift in product mix toward patented products, which rose to 64-65% of branded sales from 45% a year earlier, along with selective price increases and cost discipline. Management said delayed and irregular monsoons affected the timing of demand during the quarter but expressed confidence about improving conditions into the rest of the year.
1 statement from this call is not shown because its supporting quote could not be reproduced within our quoting limits. Nothing shown here is affected: every statement on this page carries its verified quote.
Numbers mentioned
Revenue from operations: Rs.396 crores (Q1 FY27)
p. 5
“Revenue from operations stood at Rs.396 crores compared with Rs.381 crores in Q1 FY26.”
Vikas Jain, page 5 of the filed PDF · View the filing
Gross profit: Rs.146 crores (Q1 FY27)
p. 5
“Gross profit increased by 32% year-on-year to Rs.146 crores compared with Rs.111 crores in the corresponding quarter last year.”
Vikas Jain, page 5 of the filed PDF · View the filing
Gross margin: 37% (Q1 FY27)
p. 5
“Consequently, gross margins improved to 37% from 29%, reflecting a favorable product mix, selective price increases, and our continued focus on procurement and manufacturing efficiencies.”
Vikas Jain, page 5 of the filed PDF · View the filing
EBITDA: Rs.78 crores (Q1 FY27)
p. 5
“EBITDA for the quarter stood at Rs.78 crores compared with Rs.46 crores in Q1 FY26, registering a growth of 70% year-on-year.”
Vikas Jain, page 5 of the filed PDF · View the filing
EBITDA margin: 20% (Q1 FY27)
p. 5
“EBITDA margin improved significantly to 20% compared with 12% in the same period last year.”
Vikas Jain, page 5 of the filed PDF · View the filing
Profit after tax: Rs.41 crores (Q1 FY27)
p. 5
“Profit after tax more than doubled during the quarter to Rs.41 crores compared with Rs.20 crores in Q1 FY26, representing a growth of 104%.”
Vikas Jain, page 5 of the filed PDF · View the filing
PAT margin: 10% (Q1 FY27)
p. 5
“PAT margin improved to 10% from 5% during the corresponding quarter last year, demonstrating the operating leverage in our business model.”
Vikas Jain, page 5 of the filed PDF · View the filing
Operating expenses: Rs.92.97 crores (Q1 FY27)
p. 5
“Operating expenses, including finance costs and depreciation, increased only 4.5% year-on-year to Rs.92.97 crores, despite continued investment in market development and business expansion.”
Vikas Jain, page 5 of the filed PDF · View the filing
Inventories: Rs.764 crores (as of 30th June 2026)
p. 5
“Inventories stood at Rs.764 crores as of 30th June compared to Rs.812 crores a year ago, representing a reduction of around 6%.”
Vikas Jain, page 5 of the filed PDF · View the filing
Patented portfolio contribution to branded sales: 64% (Q1 FY27)
p. 3
“we have increased the branded contribution of our patented portfolio from 45% last year Q1 to 64% in this quarter”
Surendra Sai, page 3 of the filed PDF · View the filing
Branded sales volume growth: 13% (Q1 FY27 year-on-year)
p. 5
“Our brand business continued to demonstrate healthy momentum during the quarter, with volumes of branded sales to dealers increasing by 13% year-on-year.”
Vikas Jain, page 5 of the filed PDF · View the filing
Patented portfolio volume growth: 37% (Q1 FY27 year-on-year)
p. 5
“Within this growth, our patented portfolio delivered an impressive 37% increase in volumes, reflecting the strong acceptance of our differentiated products.”
Vikas Jain, page 5 of the filed PDF · View the filing
Sales return provision: Rs.60 crores (Q1 FY27)
p. 17
“So, we have taken a number of say 20% as expected sales return and we have done a provision of around Rs. 60 crores.”
Vikas Jain, page 17 of the filed PDF · View the filing
What management said it would do
A record of statements made on the call, in the words management used. Parakho does not forecast, endorse or assess them, and their presence here is not a view on whether they will happen.
Patented portfolio share of branded sales — 60-70% · current year and future
stated as an aspiration by Vikas Jain
p. 7
“So, we believe it would be anywhere between 60 to 70% where our patent portfolio should remain out of our total branded sales.”
Vikas Jain, page 7 of the filed PDF · View the filing
EBITDA margin — 13%-14%
stated as an aspiration by Vikas Jain
p. 11
“So, 13%-14% is a pretty reasonable ask to achieve for us under normal circumstances.”
Vikas Jain, page 11 of the filed PDF · View the filing
Revenue growth CAGR — 10%-15% · each year
stated as an aspiration by Vikas Jain
p. 12
“the plan is to easily be achieve a growth of 10%-15% each year”
Vikas Jain, page 12 of the filed PDF · View the filing
Q2 demand and sales momentum — Q2 FY27
stated conditionally by Vikas Jain
p. 17
“But at least we are better off than (-40) than today (-15). And hopefully, another one week, 10 days of good rain will ensure that we do much, much better than what we anticipated.”
Vikas Jain, page 17 of the filed PDF · View the filing
QIP fundraise
stated conditionally by Vikas Jain
p. 15
“Now, we are in discussion with the investors to say, okay, what could be our next? Obviously, we don't want investors to lose their money.”
Vikas Jain, page 15 of the filed PDF · View the filing
Q&A highlights
Management's answers to analyst questions, in Parakho's words rather than a transcript. Each row names who answered and carries the verbatim quote it was drawn from.
Management attributed the improvement to discontinuing generic products and launching three new patented products, raising the patented share of branded sales, and said this level should be sustainable.
Answered by Vikas Jain
Asked by Disha Jain: What drove the gross and EBITDA margin improvement, and how sustainable is it?
p. 6
“It will be sustained because the portfolio of generic, obviously, once we have discontinued, will be lower.”
Vikas Jain, page 6 of the filed PDF · View the filing
Management cited a China price crash affecting inventory, a bad season leading to sales returns, and capacity diverted to R&D on new cost-competitive molecules.
Answered by Vikas Jain
Asked by Amit: Why did revenue and PAT decline substantially over the last three years compared to a prior 190 crore PAT level?
p. 10
“suddenly, there was a price crash, so which affected our existing inventory, and it became like we have to sell at much lower gross margins”
Vikas Jain, page 10 of the filed PDF · View the filing
Management said patented product sales continue into Q2 due to season delays and that they have created a larger sales return provision this year to reduce volatility in Q3/Q4.
Answered by Vikas Jain
Asked by Kaushik: Is the company front-loading high-margin sales in Q1 to show good numbers and taking a hit later, as in prior years?
p. 12
“we have created a buffer for the sales return provision, which we expect will start coming from September, October, so that which we are trying to reduce that volatility, which is to happen in the last 2-3 years”
Vikas Jain, page 12 of the filed PDF · View the filing
Management said patented products carry over 40% gross margin versus 15-30% for generics.
Answered by Vikas Jain
Asked by Gunit Singh: What are the margin differences between patented and generic products?
p. 13
“So, broad range is for most of the patented products, we are like +40% margin. And for generics, it's in the range of say, gross margins in the range of 15% to 25%-30%.”
Vikas Jain, page 13 of the filed PDF · View the filing
Management said it was a mix of low-cost inventory, higher-cost imports during a shortage period, and later price stabilization, not solely low-cost stock.
Answered by Vikas Jain
Asked by Gunit Singh: Were margins boosted by low-cost inventory built up before raw material price increases?
p. 13
“So, it's not necessary that our gross margins are better just because we had a huge low-cost inventory.”
Vikas Jain, page 13 of the filed PDF · View the filing
Management confirmed some sales shifted from Q1 to Q2 due to delayed rains and said capex remains on hold while a follow-up QIP is under discussion.
Answered by Vikas Jain
Asked by Sanjay: Did the delayed rain impact Q1 top line, and are plans for raising funds or capex in place?
p. 15
“CAPEX plans are on hold.”
Vikas Jain, page 15 of the filed PDF · View the filing
Management said the earlier capex-linked 20% growth projection has been revised down to 10-15% organic growth since the capex plan is on hold.
Answered by Vikas Jain
Asked by Saket Kapoor: What is the status of the earlier capex plan and its impact on growth projections?
p. 16
“But now, if you see that since it is on hold, we are back to our normal organic growth from our existing business, which is around 10% to 15%.”
Vikas Jain, page 16 of the filed PDF · View the filing
Management said they assumed a 20% sales return rate and made a provision of about Rs 60 crores, with a higher gross margin assumption built into that buffer.
Answered by Vikas Jain
Asked by Saket Kapoor: What percentage of the Q1 topline has been provisioned for sales returns?
p. 17
“So, we have taken enough buffer in this quarter itself.”
Vikas Jain, page 17 of the filed PDF · View the filing
Risks flagged
Delayed and irregular monsoons affecting sowing and demand timing
p. 2
“Delayed monsoons with irregular rainfall.”
Surendra Sai, page 2 of the filed PDF · View the filing
Above normal temperatures across agricultural regions
p. 2
“Above normal temperatures across several agricultural regions.”
Surendra Sai, page 2 of the filed PDF · View the filing
Reduced demand for seed treatment and first-round herbicide/insecticide applications due to delayed planting
p. 3
“Overall, the impact has been on seed treatment. Primarily, the demand has remained subdued due to the delayed planting, while lower crop establishment reduced the requirement for the first round of herbicide and insecticide applications primarily in soybeans, cotton, vegetables, chilies and groundnuts.”
Surendra Sai, page 3 of the filed PDF · View the filing
Rainfall deficit continuing to affect the Rabi season, particularly in the South
p. 17
“Overall, as you rightly mentioned, there is a 10% to 15% deficit in the rainfall.”
Surendra Sai, page 17 of the filed PDF · View the filing
Higher raw material costs from the U.S.-Iran conflict
p. 5
“Despite higher raw material costs arising from the U.S.-Iran conflict, we were able to successfully pass on a significant portion of the cost inflation across our product portfolio.”
Vikas Jain, page 5 of the filed PDF · View the filing
Uncertainty and delay in QIP investor fund conversion
p. 15
“So, the investors, obviously, didn't put a balance 75%.”
Vikas Jain, page 15 of the filed PDF · View the filing
Volatility from sales returns in Q3 and Q4 depending on season outcomes
p. 14
“Q3, Q4 it all depends upon how the rainfall pans out in the next two, three weeks and it all depends upon sales.”
Vikas Jain, page 14 of the filed PDF · View the filing
Ongoing pest resistance challenge in crop protection
p. 9
“In one line, there is an increasing amount of pest resistance.”
Surendra Sai, page 9 of the filed PDF · View the filing
Generated by claude-sonnet-5. Source: the transcript as filed with BSE. We link to the exchange's copy; we do not host transcripts. Parakho is a data and screening tool, not an investment adviser — nothing here is a recommendation to buy, sell or hold.